AU672984B2 - Novel oxazolidines - Google Patents

Novel oxazolidines Download PDF

Info

Publication number
AU672984B2
AU672984B2 AU44993/93A AU4499393A AU672984B2 AU 672984 B2 AU672984 B2 AU 672984B2 AU 44993/93 A AU44993/93 A AU 44993/93A AU 4499393 A AU4499393 A AU 4499393A AU 672984 B2 AU672984 B2 AU 672984B2
Authority
AU
Australia
Prior art keywords
formula
compound
pharmaceutically acceptable
compounds
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU44993/93A
Other languages
English (en)
Other versions
AU4499393A (en
Inventor
Eric Francotte
Hans-Peter Gschwind
Alfred Sallman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of AU4499393A publication Critical patent/AU4499393A/en
Application granted granted Critical
Publication of AU672984B2 publication Critical patent/AU672984B2/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG Request to Amend Deed and Register Assignors: CIBA-GEIGY AG
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D263/06—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU44993/93A 1992-09-02 1993-08-30 Novel oxazolidines Ceased AU672984B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH274292 1992-09-02
CH2742/92 1992-09-02

Publications (2)

Publication Number Publication Date
AU4499393A AU4499393A (en) 1994-03-10
AU672984B2 true AU672984B2 (en) 1996-10-24

Family

ID=4240593

Family Applications (1)

Application Number Title Priority Date Filing Date
AU44993/93A Ceased AU672984B2 (en) 1992-09-02 1993-08-30 Novel oxazolidines

Country Status (14)

Country Link
US (1) US5369117A (enExample)
EP (1) EP0586344B1 (enExample)
JP (1) JP3070812B2 (enExample)
KR (1) KR100306652B1 (enExample)
AT (1) ATE170848T1 (enExample)
AU (1) AU672984B2 (enExample)
CA (1) CA2105215C (enExample)
DE (1) DE59308970D1 (enExample)
DK (1) DK0586344T3 (enExample)
ES (1) ES2121071T3 (enExample)
IL (1) IL106862A (enExample)
NZ (1) NZ248550A (enExample)
TW (1) TW223065B (enExample)
ZA (1) ZA936393B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048857A (en) * 1989-10-17 2000-04-11 Ellinwood, Jr.; Everett H. Dosing method of administering medicaments via inhalation administration
US5503869A (en) * 1994-10-21 1996-04-02 Glaxo Wellcome Inc. Process for forming medicament carrier for dry powder inhalator
CA2163399A1 (en) * 1994-11-24 1996-05-25 Katsuhiro Kawano Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994974A (en) * 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2305092A1 (de) * 1972-02-05 1973-08-16 Yamanouchi Pharma Co Ltd Alpha-aminomethylbenzylalkoholderivate
US4219655A (en) * 1979-07-16 1980-08-26 Stauffer Chemical Company Process for the production of N-acyl substituted oxazolidines
US4407819A (en) * 1980-08-25 1983-10-04 American Cyanamid Company Phenylethanolamine derivatives and acid addition salts thereof for the depression of fat deposition in warm blooded animals
US4705798A (en) * 1985-09-27 1987-11-10 University Of Iowa Research Foundation Phenylephrine prodrug useful as mydriatic agent
US5066793A (en) * 1987-10-26 1991-11-19 Ciba-Geigy Corporation Finely particulate cellulose esters of aromatic or aromatic-aliphatic carboxylic acids, process for their preparation, and the use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994974A (en) * 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives

Also Published As

Publication number Publication date
KR940007010A (ko) 1994-04-26
IL106862A0 (en) 1993-12-28
ATE170848T1 (de) 1998-09-15
KR100306652B1 (ko) 2001-12-28
DE59308970D1 (de) 1998-10-15
DK0586344T3 (da) 1999-06-07
JPH06157487A (ja) 1994-06-03
NZ248550A (en) 1995-09-26
IL106862A (en) 1997-07-13
CA2105215A1 (en) 1994-03-03
EP0586344B1 (de) 1998-09-09
US5369117A (en) 1994-11-29
CA2105215C (en) 2004-06-29
ZA936393B (en) 1994-03-25
TW223065B (enExample) 1994-05-01
AU4499393A (en) 1994-03-10
JP3070812B2 (ja) 2000-07-31
EP0586344A1 (de) 1994-03-09
ES2121071T3 (es) 1998-11-16

Similar Documents

Publication Publication Date Title
AU611627B2 (en) Aminoethyl oxazolidinyl benzene derivatives useful as antibacterial agents
JP3255920B2 (ja) 置換ジアジン部分を含むオキサゾリジノン類とその殺菌剤としての利用
US4579854A (en) Bronchodilating 8-hydroxy-5-{(1R)-1-hydroxy-2-[N-((1R)-2-(p-methoxyphenyl)-1-methylethyl)-amino]ethyl} carbostyril
RU2073666C1 (ru) 4-[2-(2-гидрокси-2-фенилэтиламино)этокси] фенилуксусная кислота или ее биопредшественник или фармацевтически приемлемая соль, способ ее получения, композиция на ее основе
US3930016A (en) Pharmaceutical preparations containing amines useful for treatment of cardiovascular diseases
JPWO1994001392A1 (ja) （−）−リトドリン
PL198827B1 (pl) ω-Amidy N-arylosulfonyloaminokwasów, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie ω-amidów N-arylosulfonyloaminokwasów
US6066667A (en) Substituted furanones, compositions and antiarthritic use
US5369117A (en) 5-(3-formylamino-4-hydroxyphenyl)-3-(1-(4-methoxyphenyl)prop-2-yl)-oxazolidines
US20080261981A1 (en) Novel derivatives of amino acids for treatment of obesity and related disorders
FI73206C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara alkyltiofenoxipropylaminer.
US5635524A (en) Substituted oxazolidines
FI67075B (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara disubstituerade fenoletrar av 3-amino-2-hydroxipropan och salter daerav
EP0426804B1 (en) 2-(2-hydroxy-3-phenoxypropylamino)-ethoxybenzene derivatives
EP0475214A1 (en) Caffeic acid derivatives and pharmaceutical compositions containing the same
JP2010536780A (ja) 治療化合物
JP3179895B2 (ja) 新規なコハク酸誘導体
KR100245957B1 (ko) (-)-(3r)-3-메틸-4-(4-(4-(4-피리딜)피페라진-1-일)페녹시)부티르산 세포부착 저해제
EP1172359A1 (en) N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE AND USE THEREOF AS TNF-$g(a) PRODUCTION INHIBITOR
KR20020005661A (ko) Ｎ-치환되고-ｎ'-치환된 우레아 유도체 및 이를 함유하는약학 조성물
WO1992015594A1 (en) Benzamide derivatives